Italia markets close in 6 hours 14 minutes

23andMe Holding Co. (ME)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
0,4975-0,0125 (-2,45%)
Alla chiusura: 04:00PM EDT
0,5001 +0,00 (+0,52%)
Dopo ore: 07:33PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting

    23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignanciesSOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster presentations on 23ME-00610, an investigational antibody targeting CD200R1, at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meet

  • GlobeNewswire

    23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program

    23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry or ancestry from a region where sickle cell disease is common About one in 13 African Americans have the sickle cell trait. Many are unaware that they are carriers or what it means to be a carrier of the sickle cell trait SOUTH SAN FRANCISCO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human gen

  • GlobeNewswire

    23andMe Granted New FDA Clearance to Report Additional BRCA Variants

    510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prostate and pancreatic cancer Many of these additional variants occur more often in people of African American and Hispanic/Latino descent 23andMe also granted an FDA Predetermined Change Control Plan, allowing the company to update its BRCA report with additional variants without a pre-market submission, provided those variants meet the same rigor